{"nctId":"NCT00656136","briefTitle":"BIBW 2992 and BSC Versus Placebo and BSC in Non-small Cell Lung Cancer Patients Failing Erlotinib or Gefitinib (LUX-LUNG 1)","startDateStruct":{"date":"2008-04"},"conditions":["Carcinoma, Non-Small-Cell Lung"],"count":585,"armGroups":[{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: placebo"]},{"label":"BIBW 2992","type":"EXPERIMENTAL","interventionNames":["Drug: BIBW 2992"]}],"interventions":[{"name":"placebo","otherNames":[]},{"name":"BIBW 2992","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion criteria:\n\n1. Patients with pathologic confirmation of NSCLC Stage III-B (with pleural effusion) or Stage IV adenocarcinoma who have failed at least one but not more than two lines of cytotoxic chemotherapy (including adjuvant chemotherapy). One of the chemotherapy regimens must have been platinum-based.\n2. Progressive disease following at least 12 weeks of treatment with erlotinib (Tarceva速) or gefitinib (Iressa速)\n3. Eastern Cooperative Oncology Group (ECOG, R01-0787) performance Score 0, 1 or 2\n4. Patients with at least one tumor lesion that can accurately be measured by magnetic resonance imaging (MRI), or computed tomography (CT) in at least one dimension with longest diameter to be recorded as \\>20 mm using conventional techniques or \\>10 mm with spiral CT scan\n5. Male and female patients age \\>18 years\n6. Life expectancy of at least three (3) months\n7. Written informed consent that is consistent with ICH-GCP guidelines\n\nExclusion criteria:\n\n1. Use of erlotinib (Tarceva速) or gefitinib (Iressa速) within 14 days of treatment Day 1\n2. Chemo-, hormone- (other than megestrol acetate or steroids required for maintenance non-cancer therapy) or immunotherapy within the past 4 weeks\n3. Active brain metastases\n4. Significant or recent acute gastrointestinal disorders with diarrhea\n5. Patients who have any other life-threatening illness or organ system dysfunction,\n6. Other malignancies diagnosed within the past five (5) years\n7. Radiotherapy within the past 2 weeks prior to treatment\n8. History of clinically significant or uncontrolled cardiac disease\n9. Adequate ANC and platelet count\n10. Adequate liver and kidney function\n11. Patients with any serious active infection including known HIV, active hepatitis B or active hepatitis C","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Overall Survival","description":"Overall survival was the duration from the date of randomization to the date of death. Patients who were alive were censored at the last contact date prior to the database lock.\n\nFor the primary analysis 11 patients were lost to follow-up and were censored at the last contact date when they were known to be still alive. Primary analysis data cut-off date was 08 July 2010.\n\nFor the final analysis 13 patients were lost to follow-up and were censored at the last contact date when they were known to be still alive. Final analysis data cut-off date was 04 October 2013.","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11.96","spread":null},{"groupId":"OG001","value":"10.78","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11.73","spread":null},{"groupId":"OG001","value":"10.87","spread":null}]}]}]},{"type":"SECONDARY","title":"Progression-free Survival (PFS)","description":"PFS is defined as time from randomisation to disease progression or death whichever occurs first. Assessed by central independent review according to the Response Evaluation Criteria in Solid Tumours version 1.0 (RECIST 1.0).","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.08","spread":null},{"groupId":"OG001","value":"3.29","spread":null}]}]}]},{"type":"SECONDARY","title":"Objective Response Rate (OR)","description":"OR is defined as complete response (CR) and partial response (PR). Assessed by central independent review according to RECIST 1.0.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.5","spread":null},{"groupId":"OG001","value":"7.4","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":36,"n":195},"commonTop":["Diarrhoea","Rash","Decreased appetite","Paronychia","Nausea"]}}}